Omeros reported a net loss of $73.7 million, or $2.22 per share, in 2014 compared with $39.8 million, or $1.39 per share, in 2013, according to a press release.In the fourth quarter, net loss totaled $20.7 million, or $0.61 per share, compared with $1….
Author: Healio ophthalmology
Myopic shift seen 1 year after wavefront-guided myopic LASIK
A comparison of wavefront aberrometry results 1 day and 1 year after myopic LASIK showed a slight myopic shift and an increase in higher-order aberrations, according to a study.The prospective study included 105 eyes of 105 patients who underwent myopi…
VIDEO: Refractive IOL decentration
At Hawaiian Eye 2015, Uday Devgan, MD, discusses how to manage decentered multifocal IOLs.
Ocata receives EMA guidelines for Stargardt macular degeneration trial
Ocata Therapeutics received written formal guidance from the European Medicines Agency to initiate a clinical trial for its Stargardt macular degeneration program, according to a press release.The company intends on enrolling approximately 100 patients…
Imprimis reports nearly $1.7 million in total revenues in 2014
Imprimis Pharmaceuticals reported total revenues of $1.66 million in 2014 compared with $10,000 in 2013, according to a press release.In the fourth quarter 2014, revenue was $550,105 compared with $2,500 in the same quarter in 2013. An estimated $299,0…
Postoperative oculofacial plastic surgery outcomes poor in patients with body dysmorphic disorder
Using the Dysmorphic Concern Questionnaire and a population of controls, researchers found more eyelid surgeries, higher rates of post-surgical complications, increased postoperative pain and more total reoperations in patients who screened positive fo…
Highlights from OSN Europe Edition February and March cover stories
Richard B. Packard, MD, FRCS, FRCOphth, and Zoltan Z. Nagy, MD, PhD, DSc, share their commentaries on the two-part cover story on becoming a better femtosecond laser cataract surgeon from a round table discussion at the European Society of Cataract and…
InSite enters settlement agreement over patent infringement lawsuit against Mylan
InSite Vision and other plaintiffs have entered into a settlement agreement to dismiss a patent infringement lawsuit against Mylan Pharmaceuticals, according to a press release. Mylan submitted an abbreviated new drug application for marketing approval…
TearLab reports 35% increase in net revenues for fiscal year 2014
TearLab reported net revenues of $19.7 million in 2014, a 35% increase from $14.6 million in the previous year, according to a press release.Net revenues totaled $5.3 million in the fourth quarter 2014, a 19% increase from $4.4 million in the fourth qu…
Anterior capsule tear in cataract surgery may lead to poor visual, refractive outcomes
Anterior capsule tear during cataract surgery can require additional surgical procedures and may lead to worse refractive outcomes and permanent vision loss, according to a study.The retrospective interventional controlled case series consisted of 239 …
BrightFocus awards $11 million for research on vision diseases, Alzheimer’s disease
BrightFocus Foundation will award $11 million in grants to fund research on vision diseases and Alzheimer’s disease, according to a press release. BrightFocus will provide $5.1 million for macular degeneration and glaucoma research and more than $5.9 m…
Second Sight reports revenue of $3.4 million in 2014
Second Sight Medical Products reported total revenue of $3.4 million in 2014 compared with $1.6 million in 2013, according to a press release. Total revenue in the fourth quarter 2014 increased 170% to $1.5 million from $0.6 million in the same quarter…
Pattern deviation impairment in glaucoma patients may increase risk of motor vehicle collisions
Drivers with glaucoma who have severely impaired pattern deviation may have an elevated risk for being at fault in motor vehicle collisions, according to a study.The retrospective cohort study evaluated the association between binocular visual field me…
Clearside reports BCVA gain in phase 12 trial of suprachoroidal injection of triamcinolone acetonide
Patients with noninfectious uveitis experienced an improvement in best corrected visual acuity in a phase 1/2 clinical trial involving a suprachoroidal injection of triamcinolone acetonide, Clearside Biomedical reported in a press release.The trial inc…
Ocular Therapeutix reports net loss of $28.7 million in 2014
Ocular Therapeutix reported a net loss of $28.7 million, or $2.69 per share, in 2014 compared with $13.3 million, or $5.11 per share, in 2013, according to a press release. Fourth quarter 2014 net loss totaled $8 million, or $0.37 per share, compared w…
Actavis completes $70.5 billion acquisition of Allergan
Actavis announced today that it has completed its acquisition of Allergan in a transaction valued at approximately $70.5 billion in cash and equity.In a separate press release, the company also announced two former members of the Allergan board of dire…
Actavis completes $70.5 billion acquisition of Allergan
Actavis announced today that it has completed its acquisition of Allergan in a transaction valued at approximately $70.5 billion in cash and equity.In a separate press release, the company also announced two former members of the Allergan board of dire…
Povidone-iodine may have led to decrease in postoperative endophthalmitis over 20 years
Preoperative povidone-iodine treatment may be a contributing factor in the decrease of postoperative endophthalmitis over a 20-year period, according to a study. Seventy-seven out of 68,323 patients (0.113%) who underwent intraocular surgeries at a sin…
Laser-assisted cataract surgery to be broadcast live from Zlin Ophthalmology Festival
Femtosecond laser-assisted cataract surgery with implantation of recent designs of premium IOLs will be broadcast live via the Internet from the Zlin Ophthalmology Festival 2015 on Friday, March 20.Live surgery sessions from the Gemini Eye Clinic in Zl…
European Commission approves Actavis’ pending acquisition of Allergan
The European Commission has granted clearance for Actavis’ pending acquisition of Allergan, the two companies announced today.The clearance fulfilled the final regulatory condition necessary to close the pending acquisition, which is expected to be effective on or around March 17 and remains subject to customary closing conditions, according to a press release.